Corporate Profile

We are a next-generation point of care diagnostic company addressing the current limitations of legacy systems by bringing lab-comparable performance to the point of care in minutes, on a single Instrument with a low cost of ownership.

We are focused on transforming community-based healthcare by providing critical diagnostic information to healthcare providers at the point of need, thereby enabling more informed medical decisions to improve health outcomes while lowering costs.

We have developed and launched the LumiraDx Platform, which is an integrated system comprised of a small, versatile Instrument, low-cost microfluidic Test Strips, and seamless, secure digital connectivity.

With our Platform, our goal is to address the key challenges faced by healthcare providers in providing efficient and cost-effective patient care in a community setting.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

16 May '23
LONDON, May 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its first quarter ended March 31, 2023. First quarter 2023 revenues of $22.2 million.
24 Apr '23
LONDON, April 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification (the “Notification”) from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement in Nasdaq Listing Rule 5450(a)(1) for
06 Apr '23
LONDON, April 06, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a leading global provider of point-of-care diagnostics testing solutions, today announced its Strategic Refocus and Cost Restructuring Program aimed at reducing its scale and operations to pre-pandemic levels and to further